Brad is the co-founder and CSO of GoodCell and is responsible for the scientific programs and technologies employed within the company. Prior to joining GoodCell, Brad was the Chief Technology Officer for ReproCELL, Inc., a multinational stem cell company focused on the development of novel stem cell technologies and applications for research, discovery and therapeutic programs.
Preceding work as a founding Scientist and Director of Research and Development for Stemgent, Inc. resulted in the development of groundbreaking RNA-mediated cellular reprogramming technologies and applications for the generation of induced pluripotent stem cells from clinically accessible samples such as human skin, blood and urine.
Brad has both published and presented this work internationally. He is a member of the International Society of Stem Cell Research (ISSCR), also serving on the Industry Committee since 2016. Prior to joining the field of stem cell research, Brad led research teams at RheoGene and Upstate Biotech (acquired by Millipore) focused on the development of novel discovery technologies such as orthoganol, inducible mammalian gene expression switches and RNAi screening platforms.